A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
← catalyst calendarNCT06979453 · readout in 1,149 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
366estimated
Sites
132
Countries
Argentina, Belgium, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-03 | actual | When the study began enrolling |
| Primary completion | 2029-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-08-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: Deucravacitinib — also filed as BMS-986165
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)
measured At week 16
Number of participants achieving a static Physicians Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline
measured At week 16
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed